Lymphadenectomy Extent During Esophageal Cancer Surgery May Not Impact Survival

Share this content:
The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival.
The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival.

The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival, a finding that challenges current clinical guidelines, a new study published online ahead of print in JAMA Surgery has shown.1

Because the prognostic significance of the extent of lymphadenectomy during surgery for esophageal cancer is unclear, researchers sought to determine whether the number of removed lymph nodes impacts survival in patients undergoing surgery for esophageal cancer.

For the study, researchers analyzed data from 606 patients who underwent esophagectomy for esophageal cancer between 2000 and 2012, with follow-up until 2014. Of those, 83.5% had adenocarcinoma of the esophagus, 53% died within 5 years of surgery, and 39% died of tumor recurrence.

Results showed that the extent of lymphadenectomy was not statistically significantly associated with all-cause or disease-specific mortality.

Researchers found that patients who had 21 to 52 lymph nodes removed did not have a statistically significant reduction in all-cause mortality compared with those who had 10 or fewer nodes removed (HR = 0.86; 95% CI: 0.63-1.17), particularly between 2007 and 2012 (HR = 0.98; 95% CI: 0.57-1.66).

RELATED: In Resectable Esophageal, EGJ Cancer, Chemoradiotherapy Improves Survival

The study also demonstrated that a greater number of metastatic nodes and higher positive to negative node ratio was associated with increased mortality rates.

Current clinical guidelines recommend 2-field (extensive) lymphadenectomy, but in routine clinical practice, it is up to the discretion of the individual surgeon to determine the preferred extent of lymphadenectomy.

Reference

  1. Lagergren J, Mattsson F, Zylstra J, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery [published online ahead of print on September 2, 2015]. JAMA Surg. doi: 10.1001/jamasurg.2015.2611.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters